We are live on ! Find out more
LKFT

Lakefront Biotherapeutics American Depositary Shares

44 hedge funds and large institutions have $518M invested in Lakefront Biotherapeutics American Depositary Shares in 2015 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 10

41% more capital invested

Capital invested by funds: $368M → $518M (+$150M)

30% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 10

16% more funds holding

Funds holding: 3844 (+6)

Holders
44
Holders Change
+6
Holders Change %
+15.79%
% of All Funds
1.15%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
16
Increased
13
Reduced
10
Closed
10
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$246M +$580K +11,350 +0.3%
Federated Hermes
2
Federated Hermes
Pennsylvania
$69.3M +$53.3K +1,043 +0.1%
Wellington Management Group
3
Wellington Management Group
Massachusetts
$39.1M +$14.6M +285,460 +85%
BBA
4
Baker Bros. Advisors
New York
$23.2M
Goldman Sachs
5
Goldman Sachs
New York
$23.2M +$1.83M +35,712 +11%
Adage Capital Partners
6
Adage Capital Partners
Massachusetts
$18.9M -$11.6M -226,460 -43%
O
7
OrbiMed
New York
$14.5M -$14.5M -282,900 -55%
RSCM
8
Rock Springs Capital Management
Maryland
$13.2M
DM
9
Deerfield Management
New York
$11.5M -$13.2M -258,085 -59%
EC
10
EcoR1 Capital
California
$10.5M +$8.55M +167,361 New
CCP
11
Clough Capital Partners
Massachusetts
$7.91M +$6.43M +125,800 New
Morgan Stanley
12
Morgan Stanley
New York
$7.08M +$1.59M +31,019 +38%
GP
13
GLG Partners
United Kingdom
$4.42M +$3M +58,625 +502%
Point72 Asset Management
14
Point72 Asset Management
Connecticut
$4M +$3.25M +63,600 New
AA
15
ALPS Advisors
Colorado
$3.23M +$2.63M +51,393 New
EAM
16
EverPoint Asset Management
Connecticut
$3.14M +$2.55M +49,981 New
ACM
17
Atika Capital Management
New York
$2.64M -$1.2M -23,500 -36%
Renaissance Technologies
18
Renaissance Technologies
New York
$2.38M +$1.94M +37,900 New
Macquarie Group
19
Macquarie Group
Australia
$2.17M +$560K +10,952 +46%
Deutsche Bank
20
Deutsche Bank
Germany
$1.95M +$1.08M +21,101 +211%
DCM
21
DAFNA Capital Management
California
$1.89M +$1.45M +28,291 +1,655%
DCM
22
Driehaus Capital Management
Illinois
$1.69M +$1.37M +26,890 New
TCM
23
Tekla Capital Management
Massachusetts
$1.26M
WMSA
24
Weiss Multi-Strategy Advisers
New York
$912K -$307K -6,000 -29%
RSCM
25
Rail-Splitter Capital Management
Illinois
$808K -$16.1K -315 -2%

LKFT Hedge Fund Activity: Q4 2015 in Review

44 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q4 2015, worth a combined $518M — up 41% from $368M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new LKFT positions and 10 closed out — a net gain of 6 holders — while 13 added to existing stakes and 10 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $14.6M. The largest seller was Gilder Gagnon Howe & Co, exiting entirely with an estimated $23.9M sold.

  • 44 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q4 2015, up from 38 in Q3 2015.
  • Funds reported $518M of Lakefront Biotherapeutics American Depositary Shares stock for Q4 2015, up 41% quarter-over-quarter.
  • 16 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q4 2015 and 10 closed out, a net change of +6 holders.
  • The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q4 2015 was Wellington Management Group, an estimated $14.6M added.
  • The largest Lakefront Biotherapeutics American Depositary Shares seller in Q4 2015 was Gilder Gagnon Howe & Co, an estimated $23.9M sold.

Based on aggregated 13F filings for Q4 2015.